Compare IHT & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IHT | BRTX |
|---|---|---|
| Founded | 1971 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Managed Health Care |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0M | 9.7M |
| IPO Year | N/A | N/A |
| Metric | IHT | BRTX |
|---|---|---|
| Price | $1.27 | $1.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 15.6K | ★ 31.2K |
| Earning Date | 12-15-2025 | 11-12-2025 |
| Dividend Yield | ★ 1.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,443,699.00 | $383,400.00 |
| Revenue This Year | N/A | $112.14 |
| Revenue Next Year | N/A | $139.81 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1.70 |
| 52 Week Low | $1.25 | $0.98 |
| 52 Week High | $4.24 | $2.55 |
| Indicator | IHT | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.21 | 45.61 |
| Support Level | $1.32 | $1.09 |
| Resistance Level | $1.34 | $1.24 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 12.00 | 50.02 |
InnSuites Hospitality Trust is a real estate investment trust. It is engaged in the ownership and operation of hotel properties. It owns and operates hotels, provides management services for hotels, and also provides trademark license services. The Trust is also involved in various operations incidental to the operation of hotels, such as the operation of restaurants, meeting/banquet room rentals, and the operation of a reservation system. It has one reportable segment Hotel Operations & Hotel Management Services.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.